Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist

European Journal of Pharmacology

Volumn 756, Issue , 2015, Pages 1-7

  Sprecher, Dennis ^a   Maxwell, Miles ^b   Goodman, Joanne ^b   White, Brian ^b   Tang, Chi Man ^b   Boullay, Valerie ^c   De Gouville, Anne Charlotte ^c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (France)

Author keywords

Dyslipidemia; Flushing; GSK256073; Hydroxy carboxylic acid receptor 2 (HCA2); NEFA; Niacin

Indexed keywords

8 CHLORO 3 PENTYL 1H PURINE 2,6(3H,7H) DIONE; ANTILIPEMIC AGENT; CARBOXYLIC ACID DERIVATIVE; FATTY ACID; NICOTINIC ACID; PROTEIN HCA2; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; 8-CHLORO-3-PENTYL-1H-PURINE-2,6(3H,7H)-DIONE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; HCAR2 PROTEIN, HUMAN; NICOTINIC RECEPTOR; PURINE DERIVATIVE; TRIACYLGLYCEROL; XANTHINE DERIVATIVE;

ADIPOCYTE; ADULT; ANIMAL CELL; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; EAR; FATTY ACID BLOOD LEVEL; GUINEA PIG; HOT FLUSH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY TESTING; ADOLESCENT; AGONISTS; ANIMAL; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; DRUG DEVELOPMENT; DRUG EFFECTS; FLUSHING; HAMSTER; LIVER; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADIPOCYTES; ADOLESCENT; ADULT; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, NONESTERIFIED; FLUSHING; GUINEA PIGS; HUMANS; LIVER; MALE; MIDDLE AGED; PURINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; TRIGLYCERIDES; XANTHINES; YOUNG ADULT;

EID: 84925442107     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.01.051     Document Type: Article

References (26)

1. R. Altschul, A. Hoffer, and J.D. Stephen Influence of nicotinic acid on serum cholesterol in man Arch. Biochem. Biophys. 54 1955 558 559
2. Z. Benyo, A. Gille, J. Kero, M. Csiky, M.C. Suchankova, R.M. Nuesing, A. Moers, K. Pfeffer, and S. Offermanns GPR 109A (PUMA-G/GPR109A) mediates nicotinic acid-induced flushing J. Clin. Investig. 115 2005 3634 3640
3. Z. Benyo, A. Gille, C.L. Bennett, B.E. Clausen, and S. Offermanns Nicotinic acid induced flushing is mediated by activation of epidermal Langerrhans cells Mol. Pharmacol. 70 2006 1844 1849
4. R.W. Butcher, C.E. Baird, and E.W. Sutherland Effects of lipolytic and antilipolytic substances on adenosine 3′,5′-monophosphate levels in isolated fat cells J. Biol. Chem. 243 1968 1705 1712
5. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J. Intern. Med. 258 2005 94 114
6. R. Dobbins, S. Shearn, R. Byerly, F. Gao, K. Mahar, A. Napolitano, G. Nachbaur, and A.C. Le Monnier de Gouville GSK256073, a selective agonist of G-protein-coupled receptor 109A reduces serum glucose in subjects with type 2 diabetes melitus Diab. Obes. Metab. 15 2013 1013 1021
7. A. Gille, E.T. Bodor, K. Ahmed, and S. Offermanns Nicotinic acid: pharmacological effects and mechanism of action Ann. Rev. Pharmacol. Toxicol. 48 2008 79 106
8. A.C. Goldberg Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study Am. J. Cardiol. 82 1998 35U 38U
9. J. Hanson, A. Gille, S. Zwykiel, M. Lukasova, B.E. Clausen, K. Ahmed, S. Tunaru, A. Wirth, and S. Offermanns Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice J. Clin. Investig. 120 2010 2910 2919
10. HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N. Engl. J. Med. 371 2014 203 212
11. F.Y. Jin, V.S. Kamanna, and M.L. Kashyap Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport Arterioscler. Thromb. Vasc. Biol. 17 1997 2020 2028
12. P.W. Jungnickel, P.A. Maloley, E.L. Vander Tuin, T.E. Peddicord, and J.R. Campbell Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions J. Gen. Intern. Med. 12 1997 591 596
13. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J. Am. Coll. Cardiol. 61 2013 440 446
14. B. Lauring, A.K. Taggart, J.R. Tata, R. Dunbar, L. Caro, K. Cheng, J. Chin, S.L. Colletti, J. Cote, S. Khalilieh, J. Liu, W.L. Luo, A.A. Maclean, L.B. Peterson, A.B. Polis, W. Sirah, T.J. Wu, X. Liu, L. Jin, K. Wu, P.D. Boatman, G. Semple, D.P. Behan, D.T. Connolly, E. Lai, J.A. Wagner, S.D. Wright, C. Cuffie, Y.B. Mitchel, D.J. Rader, J.F. Paolini, M.G. Waters, and A. Plump Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression Sci. Transl. Med. 4 2012 10.1126/scitranslmed.3003877 148ra115
15. K. Mahboubi, T. Witman-Jones, J.E. Adamus, J.T. Letsinger, D. Whitehouse, A.R. Moorman, D. Sawicki, N. Bergenhem, and S.A. Ross Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74 Biochem. Biophys. Res. Commun. 340 2006 482 490
16. S. Offermanns The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target Trends. Pharmacol. Sci. 27 2006 384 390
17. S. Otway, and D.S. Robinson The effect of a non-ionic detergent (Triton WR 1339) on the removal of triglyceride fatty acids from the blood of the rat J. Physiol. 190 1967 309 319
18. S. Otway, and D.S. Robinson The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions J. Physiol. 190 1967 321 332
19. J.A. Pieper Overview of niacin formulations: differences in pharmacokinetics, efficacy and safety Am. J. Health. Syst. Pharm. 60 13 suppl 2 2003 S9 S14
20. J.G. Richman, M. Kanemitsu-Parks, I. Gaidarov, J.S. Cameron, P. Griffin, H. Zheng, N.C. Guerra, L. Cham, D. Maciejewski-Lenoir, D.P. Behan, D. Boatman, R. Chen, P. Skinner, P. Ornelas, M.G. Waters, S.D. Wright, G. Semple, and D.T. Connolly Nicotinic acid receptor agonists differentially activate downstream effectors J. Biol. Chem. 282 2007 18028 18036
21. G. Semple, P.J. Skinner, T. Gharbaoui, Y.J. Shin, J.K. Jung, M.C. Cherrier, P.J. Webb, S.Y. Tamura, P.D. Boatman, C.R. Sage, T.O. Schrader, R. Chen, S.L. Colletti, J.R. Tata, M.G. Waters, K. Cheng, A.K. Taggart, T.Q. Cai, E. Carballo-Jane, D.P. Behan, D.T. Connolly, and J.G. Richman 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice J. Med. Chem. 51 2008 5101 5108
22. T. Soga, M. Kamohara, J. Takasaki, S. Matsumoto, T. Saito, T. Ohishi, H. Hiyama, A. Matsuo, H. Matsushime, and K. Furuichi Molecular identification of nicotinic acid receptor Biochem. Biophys. Res. Commun. 303 2003 364 369
23. W. Soudijn, I. van Wijngaarden, and A.P. Ijzerman Nicotinic acid receptor subtypes and their ligands Med. Res. Rev. 27 2007 417 433
24. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 2011 2255 2267
25. S. Tunaru, J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, and S. Offermanns PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat. Med. 9 2003 352 355
26. A. Wise, S.M. Foord, N.J. Fraser, A.A. Barnes, N. Elshourbagy, M. Eilert, D.M. Ignar, P.R. Murdock, K. Steplewski, A. Green, A.J. Brown, S.J. Dowell, P.G. Szekeres, D.G. Hassall, F.H. Marshall, S. Wilson, and N.B. Pike Molecular identification of high and low affinity receptors for nicotinic acid J. Biol. Chem. 278 2003 9869 9874